Evidence map›Paper›PMID 35148328›Full record

ArticlePloS one2022

Psychiatric comorbidities among patients with complex drug-resistant tuberculosis in Mumbai, India.

Chinmay Laxmeshwar, Mrinalini Das, Taanya Mathur, Tarun Israni, Santosh Jha, Aparna Iyer, Mabel Morales, Tom Decroo, Tinne Gils, Gabriella Ferlazzo and 3 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Chinmay LaxmeshwarMédecins Sans Frontières, Mumbai, India.ORCID 0000-0003-1561-3857
Mrinalini DasMédecins Sans Frontières, Mumbai, India.
Taanya MathurMédecins Sans Frontières, Mumbai, India.
Tarun IsraniMédecins Sans Frontières, Mumbai, India.
Santosh JhaMédecins Sans Frontières, Mumbai, India.
Aparna IyerMédecins Sans Frontières, Mumbai, India.
Mabel MoralesMédecins Sans Frontières, Mumbai, India.
Tom DecrooInstitute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-1205-1484
Tinne GilsInstitute of Tropical Medicine, Antwerp, Belgium.
Gabriella FerlazzoSouthern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa.
Kleio IakovidiSouthern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa.
Mariana GarciaSouthern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa.
Petros IsaakidisSouthern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa.
Médecins Sans Frontières · ZAInstituut voor Tropische Geneeskunde · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeople with drug-resistant tuberculosis (DR-TB) are known to suffer from many mental-health disorders. This study aims to describe the proportion of patients diagnosed with psychiatric comorbidities, the different psychiatric diagnoses made, and treatment outcomes among DR-TB patients with or without psychiatric comorbidity and initiated on DR-TB treatment between January 2012 and March 2019 at Médecins Sans Frontières independent clinic in Mumbai, India.

methodsThis is a retrospective study using routinely collected clinical data. DR-TB care included individualised treatment, psychosocial support, and integrated psychiatric care.

resultsDuring the study period, 341 DR-TB patients were enrolled, with a median age of 25 years (IQR:20.0-36.5 years), 185 (54.2%) females, 143 (41.9%) with PreXDR-TB, and 140 (41.0%) with XDR-TB. All 341 patients were screened by a counsellor, 119 (34.9%) were referred for psychiatric evaluation, and 102 (29.9% of 341) were diagnosed with a psychiatric comorbidity. Among 102 diagnosed with a psychiatric comorbidity, 48 (47.0%) were diagnosed at baseline, and 86 (84.3%), or 25.2% of all 341 patients enrolled, were treated with psychotropic drugs. Depressive disorders were diagnosed in 49 (48.0%), mixed anxiety and depression in 24 (23.5%), neurocognitive disorders and anxiety in five (4.9%), and medication induced psychosis in two (2.0%). No anti-TB drugs were significantly associated with psychiatric comorbidities developed during treatment. Of 102 DR-TB patients with a psychiatric comorbidity, 75.5% (77) had successful DR-TB treatment outcomes, compared to 61.1% (146/239) not diagnosed with a psychiatric comorbidity (p = 0.014).

conclusionIn our setting, among people started on DR-TB treatment, and with a complex TB resistance profile, about one in three patients experienced a psychiatric comorbidity, of which half developed this comorbidity during treatment. With comprehensive psychiatric care integrated into DR-TB care delivery, treatment outcomes were at least as good among those with psychiatric comorbidities compared to those without such comorbidities.

Indexed as

AdultAntitubercular AgentsAnxietyDepressive DisorderFemaleHumansMaleNeurocognitive DisordersPsychotropic DrugsRetrospective StudiesTreatment OutcomeTuberculosis, Multidrug-ResistantYoung AdultAntitubercular AgentsPsychotropic Drugs

Identifiers

PMID35148328
PMCPMC8836323
OpenAlexW4211205445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.